A Pathology Deep Learning System Capable of Triage of Melanoma Specimens Utilizing Dermatopathologist Consensus as Ground Truth
Although melanoma occurs more rarely than several other skin cancers, patients' long term survival rate is extremely low if the diagnosis is missed. Diagnosis is complicated by a high discordance rate among pathologists when distinguishing between melanoma and benign melanocytic lesions. A tool...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , , , |
---|---|
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Although melanoma occurs more rarely than several other skin cancers,
patients' long term survival rate is extremely low if the diagnosis is missed.
Diagnosis is complicated by a high discordance rate among pathologists when
distinguishing between melanoma and benign melanocytic lesions. A tool that
allows pathology labs to sort and prioritize melanoma cases in their workflow
could improve turnaround time by prioritizing challenging cases and routing
them directly to the appropriate subspecialist. We present a pathology deep
learning system (PDLS) that performs hierarchical classification of digitized
whole slide image (WSI) specimens into six classes defined by their
morphological characteristics, including classification of "Melanocytic
Suspect" specimens likely representing melanoma or severe dysplastic nevi. We
trained the system on 7,685 images from a single lab (the reference lab),
including the the largest set of triple-concordant melanocytic specimens
compiled to date, and tested the system on 5,099 images from two distinct
validation labs. We achieved Area Underneath the ROC Curve (AUC) values of 0.93
classifying Melanocytic Suspect specimens on the reference lab, 0.95 on the
first validation lab, and 0.82 on the second validation lab. We demonstrate
that the PDLS is capable of automatically sorting and triaging skin specimens
with high sensitivity to Melanocytic Suspect cases and that a pathologist would
only need between 30% and 60% of the caseload to address all melanoma
specimens. |
---|---|
DOI: | 10.48550/arxiv.2109.07554 |